cdk15 Antibody

Which validated CDK15 antibodies are commonly used in research settings?

Based on peer-reviewed research, several validated antibodies have been successfully employed in CDK15 studies:

These antibodies have been successfully used in published research examining CDK15 expression in cancer tissues and cell lines .

What are appropriate positive controls for CDK15 antibody validation?

Based on current research, appropriate positive controls for CDK15 antibody validation include:

• Colorectal cancer tissues, particularly those from advanced cases, as CDK15 has been shown to be highly expressed in CRC

• Breast cancer tissues with confirmed high CDK15 expression (approximately 63.6% of breast cancer tissues show strong CDK15 expression)

• Recombinant CDK15 protein expressed in HEK293T cells using constructs like pcDNA3.1-CDK15-Flag, which has been used successfully in published studies

When validating a CDK15 antibody, it is recommended to include multiple positive controls alongside appropriate negative controls to ensure specificity.

How should CDK15 antibodies be optimized for immunohistochemistry (IHC) applications?

For optimal IHC detection of CDK15, the following protocol parameters have been demonstrated to be effective:

• Tissue fixation: Standard formalin fixation and paraffin embedding protocols are suitable for CDK15 detection

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer, followed by blocking with hydrogen peroxide (H₂O₂)

• Primary antibody incubation: Anti-CDK15 primary antibody (e.g., LS-B15719, Lifespan Bioscience) at 4°C overnight

• Secondary antibody incubation: Corresponding secondary antibody (e.g., from Abcam) at 37°C for 30 minutes

• Detection system: Diaminobenzidine (DAB) staining for visualization

For quantification of CDK15 expression in IHC, the Allred scoring system has been successfully employed, combining staining intensity scores [0-3] with percentage scores of stained area [0-4] to generate a final IHC score. Scores >3 typically indicate strong (high) expression, while scores ≤3 indicate weak (low) expression .

How can researchers effectively design experiments to investigate CDK15 interactions with other proteins?

When investigating CDK15 protein interactions, researchers can employ multiple complementary approaches:

• Co-immunoprecipitation (Co-IP): Effective for validating protein-protein interactions in cell lysates. This approach was successfully used to identify and confirm the interaction between CDK15 and PAK4 .

• Pull-down assays: Useful for directly testing protein interactions. For example, CDK15-NI-NTA agarose complex purified from BL-21 cells can be incubated with cancer cell lysates, followed by washing and SDS-PAGE analysis .

• Mass spectrometry: Used in conjunction with pull-down assays to identify novel interaction partners. After pull-down, discrepant gel lanes can be excised and analyzed by mass spectrometry to identify potential binding partners .

• Immunofluorescence co-localization: While not demonstrated specifically for CDK15 in the provided references, this technique has been successfully used for other CDKs (such as CDK5 co-localization with JNK3) and can be adapted for CDK15 studies.

In experimental design, appropriate controls should include CDK15-NI-NTA agarose only and cell lysates only as negative controls .

How can researchers develop specific kinase assays to measure CDK15 activity versus other CDKs?

Developing specific kinase assays for CDK15 requires careful consideration of substrate specificity and assay conditions. While the search results don't provide a specific CDK15 kinase assay protocol, insights can be drawn from related CDK assay development approaches:

• Substrate identification and specificity: Identify specific substrates of CDK15, similar to how PAK4 was identified as a CDK15 substrate . For specificity, researcher should:

  • Design synthetic peptide substrates incorporating CDK15-specific phosphorylation motifs

  • Test cross-reactivity with related kinases (e.g., other CDKs) to ensure specificity

  • Consider designing substrates with phospho-inducible detection elements, similar to the terbium-based system developed for CDK5

• In vitro kinase assay protocol: A protocol similar to that used for CDK15-PAK4 could be employed:

  • Purify active CDK15 from transfected cells (e.g., HEK293T cells transfected with pcDNA3.1-CDK15-Flag)

  • Incubate purified CDK15 (approximately 50 ng) with the substrate protein or peptide (approximately 200 ng) and 250 μM ATP

  • Conduct the reaction in kinase buffer (e.g., 20 mmol/L HEPES, pH 7.4, 10 mmol/L MgCl₂, 5 mmol/L EGTA, 150 mmol/L NaCl, 20 mmol/L β-glycerol phosphate)

  • Incubate for 30 minutes at 30°C

  • Analyze phosphorylation by western blotting with phospho-specific antibodies or mass spectrometry

• Antibody-free detection methods: Consider developing detection methods that don't rely on phospho-specific antibodies, similar to the time-resolved terbium luminescence assays developed for CDK5, which incorporate phospho-inducible terbium sensitizing motifs with kinase substrate consensus sequences .

What are the optimal strategies for using CDK15 antibodies to investigate its role in signaling pathways in different cancer types?

To comprehensively investigate CDK15's role in cancer signaling pathways, researchers should employ multi-faceted approaches:

• Combined immunohistochemistry and clinical correlation:

  • Analyze CDK15 expression in patient tissues using validated antibodies

  • Correlate expression with clinical parameters and other molecular markers

  • As demonstrated in breast cancer research, CDK15 expression can be correlated with HER2, Ki67, TNM staging, and survival outcomes

• Signaling pathway analysis with phosphorylation-specific antibodies:

  • When investigating CDK15's influence on signaling pathways, combine CDK15 antibodies with antibodies against phosphorylated forms of downstream targets

  • For colorectal cancer, antibodies against phospho-β-catenin (Ser675), phospho-ERK1/2 (Thr202/Tyr204), and phospho-MEK1/2 (Ser217/221) have been used successfully alongside CDK15 detection

  • Include total protein antibodies (e.g., β-catenin, ERK1/2, MEK1/2) to normalize phosphorylation levels

• Functional validation through genetic manipulation:

  • Use CDK15 knockdown/knockout models followed by signaling pathway analysis

  • As demonstrated in colorectal cancer research, CDK15 knockdown suppressed cell proliferation and tumor growth in vivo, which correlated with changes in β-catenin/c-Myc and MEK/ERK signaling

• Cross-cancer comparison:

  • Apply consistent antibody-based detection methods across different cancer types

  • Compare CDK15 expression patterns and signaling impacts between colorectal cancer (where it phosphorylates PAK4) and breast cancer (where it correlates with HER2 expression) to identify cancer-specific and universal mechanisms

What controls should be included when using CDK15 antibodies for western blotting and immunoprecipitation experiments?

When conducting western blotting and immunoprecipitation experiments with CDK15 antibodies, the following controls are essential:

• For western blotting:

  • Positive control: Lysate from cells or tissues known to express CDK15 (e.g., colorectal cancer or breast cancer tissues)

  • Negative control: Lysate from CDK15-knockdown or knockout cells

  • Loading control: Housekeeping proteins such as GAPDH or β-actin, which have been successfully used in CDK15 research

  • Molecular weight marker: To confirm the correct size of CDK15 (approximately 53 kDa)

• For immunoprecipitation:

  • Input control: A small portion of the lysate before immunoprecipitation

  • Negative control antibody: Pre-immune serum or isotype-matched IgG

  • Reverse IP: If studying protein-protein interactions, perform reciprocal immunoprecipitation (e.g., if studying CDK15-PAK4 interaction, perform both CDK15 IP followed by PAK4 western blot and PAK4 IP followed by CDK15 western blot)

  • Expression controls: When using tagged proteins, include controls for the tag alone

How can researchers troubleshoot weak or non-specific CDK15 antibody signals in different experimental conditions?

When encountering weak or non-specific signals with CDK15 antibodies, consider these troubleshooting strategies:

• For weak signals:

  • Optimize antibody concentration: Test a range of dilutions to find the optimal concentration

  • Increase protein loading: Ensure sufficient protein is loaded, especially for samples with lower expression

  • Enhance detection sensitivity: Use more sensitive detection systems (e.g., enhanced chemiluminescence)

  • Extended exposure times: For western blots, try longer exposure times while monitoring background

  • Consider enrichment: For low-abundance samples, consider immunoprecipitation before western blotting

• For non-specific signals:

  • Validate antibody specificity: Use CDK15 knockdown or knockout samples as negative controls

  • Optimize blocking conditions: Test different blocking agents (BSA, milk) and concentrations

  • Increase washing stringency: Use higher salt concentrations or more washing steps

  • Try alternative antibodies: Compare results with different CDK15 antibodies (e.g., PA5-28595 from Invitrogen vs. TA811934 from ORIGENE)

  • Consider tissue-specific optimization: Antibody performance may vary between tissues; protocol adjustments may be necessary when switching from colorectal to breast cancer samples

• For immunohistochemistry specifically:

  • Optimize antigen retrieval: Test different buffer systems and retrieval times

  • Adjust incubation times: Extend primary antibody incubation (e.g., overnight at 4°C as used in successful protocols)

  • Test detection systems: Compare DAB versus other chromogens for optimal visualization

What are emerging applications of CDK15 antibodies in cancer research and potential therapeutic development?

CDK15 antibodies are poised to play a critical role in several emerging research directions:

• Biomarker development: The correlation between CDK15 expression and poor prognosis in colorectal and breast cancers suggests potential for CDK15 as a prognostic or predictive biomarker . Standardized antibody-based assays could enable clinical implementation.

• Therapeutic target validation: CDK15 inhibition has shown promise in suppressing tumor growth in cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) models . Antibodies will be essential for validating target engagement in preclinical studies.

• Resistance mechanism studies: Investigating whether CDK15 contributes to resistance to existing therapies, particularly in cancers where CDK15 is highly expressed and correlates with poor outcomes.

• Combination therapy development: The correlation between CDK15 expression and other markers (e.g., HER2 in breast cancer) suggests potential for rational combination therapies. Antibody-based detection will be crucial for identifying patients most likely to benefit.

• Non-cancer applications: While current research focuses on cancer, antibody-based studies may reveal CDK15 functions in other biological contexts or diseases, similar to how CDK5 was found to function in neuronal cells .

As CDK15 research advances, continued refinement of antibody specificity, validation across diverse experimental conditions, and development of standardized protocols will be essential for reliable and reproducible results that can translate to clinical applications.